Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry

Fig. 1

Patient disposition. 1Propensity scores were calculated using baseline patient demographic data, disease characteristics (severity, duration and activity), comorbidities, past medication history and concurrent medications. Anti-TNF anti–tumor necrosis factor agent, CDAI Clinical Disease Activity Index

Back to article page